Zentalis Pharmaceuticals, Inc. (ZNTL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Company Overview - Zentalis is a small molecule oncology company focused on developing azenosertib, particularly for ovarian cancer, which is a significant area of need due to limited treatment options [2][3] Product Development - The company is currently advancing azenosertib as its lead asset, emphasizing its unique approach to treating ovarian cancer [2][3]